{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:17:11Z","timestamp":1778249831057,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Assessing the safety and efficacy of Yttrium-90 (\n                      <jats:sup>90<\/jats:sup>\n                      Y) segmentectomy and lobar radioembolization as a treatment option for patients with hepatic uveal melanoma metastases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>An IRB-approved retrospective study of patients with liver metastases from uveal melanoma treated by radioembolization from 2017 to 2023 was performed. 25 patients (9 males, 16 females) with a median age at metastatic diagnosis of 62\u00a0years (range 30\u201378) underwent a total of 52 glass radioembolization procedures. Date of diagnosis and metastasis, tumor characteristics, concomitant therapies, treatment dosage, treatment related toxicities, survival, and imaging response were collected and reviewed. Imaging response was based on RECIST criteria as well as complete or partial radiographic response of the index tumor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean index tumor size was 4.1\u2009\u00b1\u20091.0\u00a0cm (range 0.9\u201320). Complete radiographic response (n\u2009=\u200932) or partial response (n\u2009=\u200917) was achieved in 49\/52 (94%) treatments. Segmental radioembolization showed higher rates of complete radiographic response compared to lobar radioembolization (78% vs. 35%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Index tumor size was an independent factor in achieving optimal response rates for radiation segmentectomy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Overall RECIST disease control rate was 84% (21\/25). Median progression free survival and median overall survival from index treatment was 8.0\u00a0months (range 0.7\u201349.0) and 20.3\u00a0months (range 1.6\u201353.1), respectively. One year survival was 76% (19\/25). Twelve mild Grade 1a clinical toxicities were reported (48%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study supports\n                      <jats:sup>90<\/jats:sup>\n                      Y radioembolization as a safe and effective treatment option for patients with hepatic metastatic uveal melanoma, with radiation segmentectomy achieving high rates of radiographic response and disease control rates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00270-026-04373-y","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T03:44:52Z","timestamp":1771559092000},"page":"937-947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases"],"prefix":"10.1007","volume":"49","author":[{"given":"Jason R.","family":"Ni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Quirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Chmielowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3975-7479","authenticated-orcid":false,"given":"Siddharth A.","family":"Padia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"1","key":"4373_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101(1):38\u201344. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309034.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"4373_CR2","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/cncr.20866","volume":"103","author":"CC McLaughlin","year":"2005","unstructured":"McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103(5):1000\u20137. https:\/\/doi.org\/10.1002\/cncr.20866.","journal-title":"Cancer"},{"issue":"1","key":"4373_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1055\/s-0033-1333652","volume":"30","author":"DJ Eschelman","year":"2013","unstructured":"Eschelman DJ, Gonsalves CF, Sato T. Transhepatic therapies for metastatic uveal melanoma. Semin Intervent Radiol. 2013;30(1):39\u201348. https:\/\/doi.org\/10.1055\/s-0033-1333652.","journal-title":"Semin Intervent Radiol"},{"issue":"1","key":"4373_CR4","doi-asserted-by":"publisher","first-page":"647684","DOI":"10.1155\/2012\/647684","volume":"2012","author":"F Tas","year":"2012","unstructured":"Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012;2012(1):647684. https:\/\/doi.org\/10.1155\/2012\/647684.","journal-title":"J Oncol"},{"issue":"5","key":"4373_CR5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0161-6420(03)00077-0","volume":"110","author":"AD Singh","year":"2003","unstructured":"Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110(5):962\u20135. https:\/\/doi.org\/10.1016\/S0161-6420(03)00077-0.","journal-title":"Ophthalmology"},{"issue":"2","key":"4373_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/1097-0142(19830715)52:2<334::AID-CNCR2820520225>3.0.CO;2-E","volume":"52","author":"S Rajpal","year":"1983","unstructured":"Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52(2):334\u20136.","journal-title":"Cancer"},{"issue":"1","key":"4373_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40487-018-0056-8","volume":"6","author":"M Singh","year":"2018","unstructured":"Singh M, Durairaj P, Yeung J. Uveal melanoma: a review of the literature. Oncol Ther. 2018;6(1):87\u2013104. https:\/\/doi.org\/10.1007\/s40487-018-0056-8.","journal-title":"Oncol Ther"},{"key":"4373_CR8","doi-asserted-by":"publisher","unstructured":"Rao PK, Barker C, Coit DG, et al. NCCN guidelines insights: uveal melanoma, version 1.2019. Published online February 1, 2020. https:\/\/doi.org\/10.6004\/jnccn.2020.0007","DOI":"10.6004\/jnccn.2020.0007"},{"issue":"13","key":"4373_CR9","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2103485.","journal-title":"N Engl J Med"},{"issue":"24","key":"4373_CR10","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, Piperno-Neumann S, Rutkowski P, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24):2256\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2304753.","journal-title":"N Engl J Med"},{"issue":"6","key":"4373_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.20.00550","volume":"39","author":"JM Piulats","year":"2021","unstructured":"Piulats JM, Espinosa E, de la Cruz Merino L, et al. Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39(6):586\u201398. https:\/\/doi.org\/10.1200\/JCO.20.00550.","journal-title":"J Clin Oncol"},{"key":"4373_CR12","unstructured":"Guidelines Detail. NCCN. Accessed 11 Jan 2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1488"},{"issue":"10","key":"4373_CR13","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/14737140.2022.2124971","volume":"22","author":"LN Chen","year":"2022","unstructured":"Chen LN, Carvajal RD. Tebentafusp for the treatment of HLA-A*02:01\u2013positive adult patients with unresectable or metastatic uveal melanoma. Expert Rev Anticancer Ther. 2022;22(10):1017\u201327. https:\/\/doi.org\/10.1080\/14737140.2022.2124971.","journal-title":"Expert Rev Anticancer Ther"},{"key":"4373_CR14","unstructured":"HEPZATO KITTM. HEPZATO KITTM. Accessed 12 Jan 2026. https:\/\/hepzatokit.com\/"},{"issue":"3","key":"4373_CR15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00270-022-03338-1","volume":"46","author":"TML Tong","year":"2023","unstructured":"Tong TML, Burgmans MC, Speetjens FM, et al. Combining melphalan percutaneous hepatic perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: first safety and efficacy data from the phase Ib part of the Chopin trial. Cardiovasc Intervent Radiol. 2023;46(3):350\u20139. https:\/\/doi.org\/10.1007\/s00270-022-03338-1.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"16","key":"4373_CR16","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JCO.22.01705","volume":"41","author":"R Olofsson Bagge","year":"2023","unstructured":"Olofsson Bagge R, Nelson A, Shafazand A, et al. Isolated hepatic perfusion with melphalan for patients with isolated uveal melanoma liver metastases: a multicenter, randomized, open-label, phase III trial (the SCANDIUM trial). J Clin Oncol. 2023;41(16):3042\u201350. https:\/\/doi.org\/10.1200\/JCO.22.01705.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4373_CR17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cncr.28480","volume":"120","author":"SS Agarwala","year":"2014","unstructured":"Agarwala SS, Eggermont AMM, O\u2019Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer. 2014;120(6):781\u20139. https:\/\/doi.org\/10.1002\/cncr.28480.","journal-title":"Cancer"},{"issue":"1","key":"4373_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1148\/radiol.2019190199","volume":"293","author":"CF Gonsalves","year":"2019","unstructured":"Gonsalves CF, Eschelman DJ, Adamo RD, et al. A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology. 2019;293(1):223\u201331. https:\/\/doi.org\/10.1148\/radiol.2019190199.","journal-title":"Radiology"},{"issue":"1","key":"4373_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/COC.0000000000000109","volume":"40","author":"M Xing","year":"2017","unstructured":"Xing M, Prajapati HJ, Dhanasekaran R, et al. Selective internal yttrium-90 radioembolization therapy (90Y-SIRT) versus best supportive care in patients with unresectable metastatic melanoma to the liver refractory to systemic therapy: safety and efficacy cohort study. Am J Clin Oncol. 2017;40(1):27\u201334. https:\/\/doi.org\/10.1097\/COC.0000000000000109.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"4373_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jvir.2016.09.024","volume":"28","author":"SA Padia","year":"2017","unstructured":"Padia SA, Lewandowski RJ, Johnson GE, et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol. 2017;28(1):1\u201315. https:\/\/doi.org\/10.1016\/j.jvir.2016.09.024.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"4373_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1053\/j.tvir.2019.02.008","volume":"22","author":"SA Padia","year":"2019","unstructured":"Padia SA. Y90 clinical data update: cholangiocarcinoma, neuroendocrine tumor, melanoma, and breast cancer metastatic disease. Tech Vasc Interv Radiol. 2019;22(2):81\u20136. https:\/\/doi.org\/10.1053\/j.tvir.2019.02.008.","journal-title":"Tech Vasc Interv Radiol"},{"key":"4373_CR22","doi-asserted-by":"publisher","unstructured":"O\u2019Donohoe RL, Stedman B. 35\u2014transcatheter embolization of liver metastases. In: Mauro MA, Murphy KP, Thomson KR, Venbrux AC, Morgan RA, editors. Image-guided interventions (Third Edition). Expert Radiology. Amsterdam: Elsevier; 2020. pp. 287--296.e3. https:\/\/doi.org\/10.1016\/B978-0-323-61204-3.00035-X.","DOI":"10.1016\/B978-0-323-61204-3.00035-X"},{"key":"4373_CR23","doi-asserted-by":"publisher","unstructured":"Boas FE, Sofocleous CT. 36\u2014embolotherapy for the management of liver malignancies other than hepatocellular carcinoma. In: Mauro MA, Murphy KP, Thomson KR, Venbrux AC, Morgan RA, editors. Image-Guided Interventions (Third Edition). Expert Radiology. Amsterdam: Elsevier; 2020. pp. 297\u2013300.e1. https:\/\/doi.org\/10.1016\/B978-0-323-61204-3.00036-1.","DOI":"10.1016\/B978-0-323-61204-3.00036-1"},{"issue":"1","key":"4373_CR24","doi-asserted-by":"publisher","first-page":"107327482098301","DOI":"10.1177\/1073274820983019","volume":"27","author":"MJ Carr","year":"2020","unstructured":"Carr MJ, Sun J, Cohen JB, et al. Over 12 years single institutional experience performing percutaneous hepatic perfusion for unresectable liver metastases. Cancer Control. 2020;27(1):1073274820983019. https:\/\/doi.org\/10.1177\/1073274820983019.","journal-title":"Cancer Control"},{"issue":"1","key":"4373_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/cancers12010117","volume":"12","author":"RS Seedor","year":"2020","unstructured":"Seedor RS, Eschelman DJ, Gonsalves CF, et al. An outcome assessment of a single institution\u2019s longitudinal experience with uveal melanoma patients with liver metastasis. Cancers. 2020;12(1):117. https:\/\/doi.org\/10.3390\/cancers12010117.","journal-title":"Cancers"},{"issue":"2","key":"4373_CR26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1245\/s10434-020-08741-x","volume":"28","author":"TS Meijer","year":"2021","unstructured":"Meijer TS, Burgmans MC, de Leede EM, et al. Percutaneous hepatic perfusion with melphalan in patients with unresectable ocular melanoma metastases confined to the liver: a prospective phase II study. Ann Surg Oncol. 2021;28(2):1130\u201341. https:\/\/doi.org\/10.1245\/s10434-020-08741-x.","journal-title":"Ann Surg Oncol"},{"key":"4373_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-3-030-28891-4_27","volume-title":"Cancer regional therapy: HAI, HIPEC, HILP, ILI, PIPAC and beyond","author":"TS Meijer","year":"2020","unstructured":"Meijer TS, Vahrmeijer AL, Burgmans MC. Regional therapies for hepatic melanoma metastases. In: Fong Y, Gamblin TC, Han ES, Lee B, Zager JS, editors. Cancer regional therapy: HAI, HIPEC, HILP, ILI, PIPAC and beyond. Cham: Springer International Publishing; 2020. p. 323\u201340. https:\/\/doi.org\/10.1007\/978-3-030-28891-4_27."},{"issue":"2","key":"4373_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00270-019-02366-8","volume":"43","author":"AO Levey","year":"2020","unstructured":"Levey AO, Elsayed M, Lawson DH, et al. Predictors of overall and progression-free survival in patients with ocular melanoma metastatic to the liver undergoing Y90 radioembolization. Cardiovasc Intervent Radiol. 2020;43(2):254\u201363. https:\/\/doi.org\/10.1007\/s00270-019-02366-8.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"4373_CR29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.2967\/jnumed.119.230870","volume":"61","author":"A Ponti","year":"2020","unstructured":"Ponti A, Denys A, Digklia A, et al. First-line selective internal radiation therapy in patients with uveal melanoma metastatic to the liver. J Nucl Med. 2020;61(3):350\u20136. https:\/\/doi.org\/10.2967\/jnumed.119.230870.","journal-title":"J Nucl Med"},{"issue":"4","key":"4373_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.hpb.2019.11.002","volume":"22","author":"A Rowcroft","year":"2020","unstructured":"Rowcroft A, Loveday BPT, Thomson BNJ, Banting S, Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB. 2020;22(4):497\u2013505. https:\/\/doi.org\/10.1016\/j.hpb.2019.11.002.","journal-title":"HPB"},{"key":"4373_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/978-3-030-39021-1_14","volume-title":"Imaging of the liver and intra-hepatic biliary tract: volume 2: tumoral pathologies","author":"C Mosconi","year":"2021","unstructured":"Mosconi C, Golfieri R. Transarterial 90Yttrium radioembolisation. In: Quaia E, editor. Imaging of the liver and intra-hepatic biliary tract: volume 2: tumoral pathologies. Cham: Springer International Publishing; 2021. p. 319\u201347. https:\/\/doi.org\/10.1007\/978-3-030-39021-1_14."},{"key":"4373_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/978-3-030-82639-0_14","volume-title":"Melanoma in clinical practice","author":"MA Dyer","year":"2021","unstructured":"Dyer MA, Lam CM, Qureshi MM, Truong MT. Radiation therapy in advanced melanoma. In: Alani RM, Sahni D, editors. Melanoma in clinical practice. Cham: Springer International Publishing; 2021. p. 239\u201368. https:\/\/doi.org\/10.1007\/978-3-030-82639-0_14."},{"issue":"1","key":"4373_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jso.26223","volume":"123","author":"SA Padia","year":"2021","unstructured":"Padia SA, Johnson GE, Agopian VG, et al. Yttrium-90 radiation segmentectomy for hepatic metastases: a multi-institutional study of safety and efficacy. J Surg Oncol. 2021;123(1):172\u20138. https:\/\/doi.org\/10.1002\/jso.26223.","journal-title":"J Surg Oncol"},{"issue":"5","key":"4373_CR34","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, et al. Yttrium\u201090 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342\u201352. https:\/\/doi.org\/10.1002\/hep.31819.","journal-title":"Hepatology"},{"key":"4373_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-025-04200-w","author":"D Filippiadis","year":"2025","unstructured":"Filippiadis D, Pereira PL, Hausegger KA, Ryan AG, Binkert CA. CIRSE standards of practice for the classification of complications: the modified CIRSE classification system. Cardiovasc Intervent Radiol. 2025. https:\/\/doi.org\/10.1007\/s00270-025-04200-w.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"4373_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"4373_CR37","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. Accessed 14 Sep 2024. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_60."},{"issue":"8","key":"4373_CR38","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jvir.2023.05.003","volume":"34","author":"SN Mourad","year":"2023","unstructured":"Mourad SN, Garza-Ramos CDla, Toskich BB. Radiation segmentectomy above 1,000 Gy for the treatment of hepatocellular carcinoma: is there a dose limit? J Vasc Interv Radiol. 2023;34(8):1458\u201362. https:\/\/doi.org\/10.1016\/j.jvir.2023.05.003.","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"4373_CR39","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.ebiom.2015.09.019","volume":"2","author":"M Terai","year":"2015","unstructured":"Terai M, Mu Z, Eschelman DJ, et al. Arterial blood, rather than venous blood, is a better source for circulating melanoma cells. EBioMedicine. 2015;2(11):1821\u20136. https:\/\/doi.org\/10.1016\/j.ebiom.2015.09.019.","journal-title":"EBioMedicine"},{"issue":"5","key":"4373_CR40","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/ijc.28436","volume":"134","author":"FC Bidard","year":"2014","unstructured":"Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer. 2014;134(5):1207\u201313. https:\/\/doi.org\/10.1002\/ijc.28436.","journal-title":"Int J Cancer"},{"issue":"9","key":"4373_CR41","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","volume":"118","author":"AD Singh","year":"2011","unstructured":"Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881\u20135. https:\/\/doi.org\/10.1016\/j.ophtha.2011.01.040.","journal-title":"Ophthalmology"},{"issue":"10","key":"4373_CR42","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jvir.2018.04.030","volume":"29","author":"J Zheng","year":"2018","unstructured":"Zheng J, Irani Z, Lawrence D, Flaherty K, Arellano RS. Combined effects of Yttrium-90 transarterial radioembolization around immunotherapy for hepatic metastases from uveal melanoma: a preliminary retrospective case\u00a0series. J Vasc Interv Radiol. 2018;29(10):1369\u201375. https:\/\/doi.org\/10.1016\/j.jvir.2018.04.030.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"4373_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","volume":"7","author":"MV Heppt","year":"2019","unstructured":"Heppt MV, Amaral T, K\u00e4hler KC, et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer. 2019;7(1):299. https:\/\/doi.org\/10.1186\/s40425-019-0800-0.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"4373_CR44","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1245\/s10434-024-15293-x","volume":"31","author":"JS Zager","year":"2024","unstructured":"Zager JS, Orloff M, Ferrucci PF, et al. Efficacy and safety of the melphalan\/hepatic delivery system in patients with unresectable metastatic uveal melanoma: results from an open-label, single-arm, multicenter phase 3 study. Ann Surg Oncol. 2024;31(8):5340\u201351. https:\/\/doi.org\/10.1245\/s10434-024-15293-x.","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"4373_CR45","doi-asserted-by":"publisher","first-page":"4942","DOI":"10.3390\/cancers15204942","volume":"15","author":"M Kolb","year":"2023","unstructured":"Kolb M, Forschner A, Artzner C, et al. Selective internal radiotherapy (SIRT) and chemosaturation percutaneous hepatic perfusion (CS-PHP) for metastasized uveal melanoma: a retrospective comparative study. Cancers. 2023;15(20):4942. https:\/\/doi.org\/10.3390\/cancers15204942.","journal-title":"Cancers"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04373-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-026-04373-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04373-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:56:22Z","timestamp":1778248582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-026-04373-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4373"],"URL":"https:\/\/doi.org\/10.1007\/s00270-026-04373-y","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jason R. Ni: None. Matthew Quirk: None. Bartosz Chmielowski: Advisory Board: Treeline Biosciences, Fortvita Biologics, Immunocore. Data Monitoring Committee: Servier, SpringWorks Therapeutics, TuHura. Clinical Trial Support: Bristol-Myers Squibb, Macrogenics, Infinity Pharmaceuticals, Advenchen Laboratories, Xencor, Compugen, Iovance, RAPT Therapeutics, IDEAYA Biosciences, Ascentage, Atreca, Replimune, InstilBio, Adagene, TriSalus Life Sciences, Kinnate, PTC Therapeutics, Xilio Therapeutics, Kezar Life Sciences, Immunocore, AskGene Pharma, Krystal bio, Nested Therapeutics, Pierre Fabre, Georgiamune, Immatics, Regeneron. Siddharth A. Padia: Consultant for Boston Scientific, Teleflex, Varian Medical Systems, Terumo, Next Medical, Crannmed, Easai, Johnson and Johnson, Merit, Philips, BD, Asahi, and Delcath. Research grant: Varian and Boston Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has obtained IRB approval from the UCLA Human Research Protection Program (IRB Approval #23\u2013000622) and the need for informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}